Announcement on the Handling of Relevant Tax Matters
Filed with SSE · · 2 pages · Chinese
Earlier from BeOne Medicines
- Indicative Announcement on Change in Equity of Shareholders with Over 5% Shares Reaching 1% Scale
- BeOne Medicines’ BEQALZI™ (sonrotoclax) Approved by U.S. FDA as First and Only BCL2 Inhibitor for R/R Mantle Cell Lymphoma
- Report for Q1 2026
- BeOne Medicines Announces First Quarter 2026 Financial Results and Business Updates
- U.S. FDA Grants Priority Review to BeOne Medicines’ TEVIMBRA in First-Line HER2+ GEA
Later from BeOne Medicines
- Voluntary Announcement on Progress of Clinical Trial of BRUKINSA (Zanubrutinib Capsules)
- Grant of Restricted Share Units
- Announcement on Voluntary Disclosure of Holding Conference Call for Company Performance
- Announcement on Voluntary Disclosure of Adjustment of Operating Performance Forecast for 2026
- Announcement on Convening the 2026 Semi-annual Performance Briefing
Follow BeOne Medicines into a list and get an email when it puts out news.
Follow BeOne Medicines